Introduction
============

Mucinous gastric carcinoma (MGC) is considered a special histologic type of gastric adenocarcinoma with a substantial amount of extracellular mucin (≥50% of tumor volume) within tumor areas defined by the World Health Organization (WHO).[@b1-ott-11-967],[@b2-ott-11-967] Recently, some studies focussed on the MGC.[@b3-ott-11-967]--[@b5-ott-11-967] Tang et al[@b6-ott-11-967] found that MGC was an aggressive malignancy with unique clinicopathological features in 244 MGC patients who underwent radical gastrectomy with D2 lymphadenectomy. In Isobe et al's study,[@b7-ott-11-967] 70 MGC patients were compared with 2,492 non-MGC (NMGC) patients, and although MGC is rarer and mostly detected at an advanced stage, the diagnosis of the mucinous histological subtype was not an independent prognostic factor. Zhao et al's results showed MGC was more likely to have large tumors and more advanced tumor stage (II and III) than NMGC, and the thicker gastric wall, layered enhancement pattern, and calcification were highly suggestive computed tomography features for differentiating MGC from NMGC.[@b8-ott-11-967] It is been stated that this subtype of gastric adenocarcinoma seems to be accompanied by advanced tumor stage and poor prognosis,[@b9-ott-11-967] but the molecular markers in this histologic type remain unknown.

In 2014, Park et al reported on the prognostic significance of neuroendocrine components in GC, finding that different proportions of neuroendocrine components might indicate different prognoses.[@b10-ott-11-967] Also, the mucinous component has been observed in gastric adenocarcinoma frequently,[@b11-ott-11-967],[@b12-ott-11-967] but the biological characteristics and prognosis of mucinous component in gastric adenocarcinoma after radical D2 gastrectomy are not yet clear. In this study, we explored the clinicopathologic (especially molecular tumor and pathology markers) and prognostic significance of mucinous component in gastric adenocarcinoma after radical D2 gastrectomy according to proportion.

Patients and methods
====================

Selection of patients
---------------------

Candidate patients who had undergone radical D2 gastrectomy for gastric adenocarcinoma in the Division of Digestive Surgery of Xijing Digestive Hospital between September 2008 and May 2015 were enrolled. This retrospective study adhered to the guidelines established by the Declaration of Helsinki and was approved by the institutional review board of Xijing Hospital. Signed informed consent forms were received from all enrolled patients. All patients were evaluated carefully for anesthesia and operation safety. Patients had undergone radical D2 gastrectomy as the standard approach, and pathologic diagnosis was done by at least two trained and experienced gastrointestinal pathologists using the WHO criteria.[@b13-ott-11-967]--[@b15-ott-11-967]

Data collection
---------------

Clinicopathologic characters for each patient -- age, sex, history of drinking and smoking, tumor location, Borrmann type, tumor biomarkers (AFP, CEA, CA125, CA19-9), molecular pathological markers (S100, EGFR, HER2) -- were obtained from surgical records, medical charts, and postoperative histopathology reports. We collected data on depth of invasion and lymph-node metastasis instead of pathological stage, in order to assess the significance of different T and N stages on prognosis separately.

Prognosis and statistical analysis
----------------------------------

Gastric adenocarcinoma patients with or without mucinous component were selected based on T and N stage, tumor location, and Borrmann type, while patients with various proportions of mucinous component were accessed based on T stage and Borrmann type, in order to reduce differences in clinicopathological characteristics, using Gmatch methods.

Selected patients were followed up according to standard protocol (3-month interval for the first 2 years, every 6 months for the subsequent 3 years, and yearly thereafter) for 1--67 months. The 5-year overall survival rate was estimated by Kaplan--Meier method and compared by log-rank test. The Cox proportional hazard model was employed for multivariate analysis. All statistical analyses were performed with SPSS version 19.0. *P*-values \<0.05 were considered statistically significant, and all tests were two-sided.

Results
=======

Patient features
----------------

A total of 6,205 patients with gastric cancer were admitted to our division from September 2008 to May 2015, and 3,537 adenocarcinoma patients were enrolled, including 176 MGC (≥50% of extracellular mucin within tumors areas), 514 gastric adenocarcinoma with mucinous component (GAM; 0--50% extracellular mucin within tumor areas), and 2,847 pure gastric adenocarcinoma (PGA) without mucinous component (without extracellular mucin within tumor areas).

Comparison between gastric adenocarcinoma with and without mucinous component
-----------------------------------------------------------------------------

GAM and MGC patients were mostly female, younger (\<60 years), with drinking history, lower tumor location, Borrmann types III and IV, T4 stage, and more lymph-node metastasis ([Table 1](#t1-ott-11-967){ref-type="table"}). Analysis of molecular markers showed more positive expression of CEA, CA19-9, and S100 and less positive expression of AFP and HER2 (\>++ and fluorescence in situ hybridization) in GAM and MGC than in PGA ([Table 1](#t1-ott-11-967){ref-type="table"}). By Gmatch, 646 pairs were obtained and assessed, with the overall rate of visits available for analysis at 96.5%. The 5-year overall survival rate showed no significant difference between patients with or without mucinous component after radical D2 gastrectomy, even with different T stages ([Figure 1](#f1-ott-11-967){ref-type="fig"}). Ten factors assessed in univariate analysis had significant influence on long-term survival ([Table 2](#t2-ott-11-967){ref-type="table"}). Multivariate analysis indicated T stage, N stage, and CEA were independent prognostic factors, while existence of mucinous component in gastric adenocarcinoma was not a prognostic factor for patients after radical D2 gastrectomy ([Table 2](#t2-ott-11-967){ref-type="table"}).

Comparison among various proportions of mucinous component
----------------------------------------------------------

Compared with GAM, MGC occurred more frequently in Borrmann type III and IV, with more T4 stage ([Table 1](#t1-ott-11-967){ref-type="table"}). As for molecular markers, positive expression of CA19-9 in MGC was higher than that of GAM (*P*\<0.05), while the positive rate of EGFR and HER2 (\>++ and fluorescence in situ hybridization) in MGC was less than that of GAM (*P*\<0.05) ([Table 3](#t3-ott-11-967){ref-type="table"}). With the same approach by Gmatch, 155 pairs were selected, with overall visits available for analysis also at 96.5%. MGC and GAM had similar 5-year overall survival rates (*P*\>0.05) ([Figure 2](#f2-ott-11-967){ref-type="fig"}). When compared with prognosis by T stage, data showed no significant differences (*P*\>0.05) ([Figure 2](#f2-ott-11-967){ref-type="fig"}). Eight factors evaluated in univariate analysis had a significant influence on long-term survival ([Table 3](#t3-ott-11-967){ref-type="table"}). Multivariate analysis indicated that independent prognostic factors were N stage and CEA, and proportion of mucinous component in gastric adenocarcinoma was not a prognostic factor for patients after radical D2 gastrectomy ([Table 4](#t4-ott-11-967){ref-type="table"}).

Discussion
==========

Gastric adenocarcinoma is one of the most common cancers in developing countries, especially in China. Because of its heterogeneity, therapeutic effectiveness is not satisfactory, which might be due to different proportions of histologic component. MGC is considered a special subtype of gastric adenocarcinoma, and MGC characteristics have been reported by several studies as deeper invasion, lower location, more lymph-node metastasis, and poor prognosis.[@b2-ott-11-967],[@b6-ott-11-967],[@b9-ott-11-967],[@b16-ott-11-967],[@b17-ott-11-967] In Zu et al's study, MGC survival was correlated with stage at diagnosis and mucinous histologic type was an independent prognostic factor.[@b16-ott-11-967] Yin et al compared 196 MGC with 2,573 PGA samples, which showed MGC was more advanced at the time of diagnosis and received less curative gastrostomy, but the prognosis of MGC was not significantly different from PGA after curative gastrostomy.[@b2-ott-11-967] For patients in our division, MGC is a rare histologic type in gastric adenocarcinoma and diagnosed mostly in an advanced stage, but is not a prognostic significance after radical D2 gastrectomy.[@b9-ott-11-967]

Lots of studies have reported on the clinical--pathological characteristics and prognosis of MGC,[@b4-ott-11-967],[@b6-ott-11-967],[@b7-ott-11-967],[@b18-ott-11-967] but few have focused on the prognostic significance of mucinous component in gastric adenocarcinoma, even though the coexistence of mucinous component and gastric adenocarcinoma is observed frequently. Kim et al[@b19-ott-11-967] revealed there were some differences in several clinicopathological features of signet-ring cell, mucinous (MGC), papillary, and lymphoepithelioma-like subtypes of advanced gastric cancer, and no statistical differences in survival were found among these after R0 gastrectomy. In another study,[@b17-ott-11-967] clinical and pathological features and prognoses of GMC and gastric signet-ring cell types differed. Therefore, the treatment of the two diseases should be individualized.

In 2014, Park et al[@b10-ott-11-967] explored the prognostic significance of neuroendocrine components in GC and found different proportions of neuroendocrine components led to different prognoses. In this study, we assessed differences among various proportions of mucinous component to explore the prognostic significance of mucinous component in gastric adenocarcinoma after radical D2 gastrectomy. We found that characteristics of gastric adenocarcinoma with the presence of mucinous component in patients of a more advanced stage, who were younger and female, with a drinking history, and in those with gastric adenocarcinoma in the lower stomach, even though it is said that the incidence of gastric adenocarcinoma in the upper stomach increases year by year. However, the two groups had similar prognoses, even in different T stages. The exit of mucinous component in gastric adenocarcinoma was not an independent prognostic factor after radical D2 gastrectomy. The results told us that more mucinous component in gastric adenocarcinoma did not lead to worse prognosis after radical D2 gastrectomy, and N stage and CEA were independent prognostic factors, while the proportion of mucinous component was not.

In our opinion, the tumor microenvironment of gastric adenocarcinoma with mucinous component might play a very important role. Age and sex might affect hormonal levels, especially estrogen. It seems that the mucinous component might secrete some unknown kind of substance to reduce clinical symptoms, which may be the reason more advanced stages were found. Also, alcohol intake for a long time might change the microenvironment. The MGC-specific tumor microenvironment might alter the binding sites of the molecular markers. It is said that the different functions are caused by different structure, so the higher morbidity of gastric adenocarcinoma in distal gastric might be caused by the enrichment of mucinous cells in glands of this area. However, all these hypotheses need further investigation.

Conclusion
==========

Whatever its various proportions, mucinous component is not a significant prognosis factor in gastric adenocarcinoma after radical D2 gastrectomy. Specific clinicopathological characteristics and molecular markers with significant differences might provide a potential strategy for optimal individual diagnosis and therapy for gastric adenocarcinoma patients with any proportion of mucinous component. The results of this research should be further confirmed in multicenter studies for future clinical use.
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###### 

Various proportions of mucinous component showed no difference in OS after radical D2 gastrectomy, even assessed by T stage.

**Abbreviations:** OS, overall survival; MGC, mucinous gastric carcinoma; GAM, gastric adenocarcinoma with mucinous component; PGA, pure gastric adenocarcinoma.
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###### 

Clinicopathological characteristics of patients with/without mucinous component

  Variables                   With, n=690   Without, n=2,847   *P*-value
  --------------------------- ------------- ------------------ -----------
  **Age, years**                                               0.018
  ≤30                         12 (1.7%)     32 (1.1%)          
  31--40                      47 (6.8%)     153 (5.4%)         
  41--50                      136 (19.7%)   524 (18.4%)        
  51--60                      251 (36.4%)   913 (32.1%)        
  61--70                      173 (25.1%)   857 (30.1%)        
  71--80                      67 (9.7%)     350 (12.3%)        
  \>80                        4 (0.6%)      18 (0.6%)          
  **Sex**                                                      0.009
  Male                        512 (74.2%)   2,244 (78.8%)      
  Female                      178 (25.8%)   603 (21.2%)        
  **Smoking history**                                          0.083
  Yes                         594 (86.1%)   2,374 (83.4%)      
  No                          96 (13.9%)    473 (16.6%)        
  **Drinking history**                                         0.000
  Yes                         209 (30.3%)   342 (12%)          
  No                          481 (69.7%)   1,505 (88%)        
  **Location**                                                 0.035
  Upper                       211 (30.6%)   998 (35.1%)        
  Middle                      118 (17.1%)   513 (18%)          
  Lower                       345 (50%)     1,295 (45.5%)      
  Whole                       16 (2.3%)     41 (1.4%)          
  **Macroscopic type**                                         0.001
  Early gastric cancer        87 (13.3%)    518 (19%)          
  Borrmann I                  47 (7.2%)     207 (7.6%)         
  Borrmann II                 153 (23.3%)   686 (25.2%)        
  Borrmann III                290 (44.2%)   1,070 (39.3%)      
  Borrmann IV                 79 (12%)      240 (8.8%)         
  **Depth on invasion**                                        0.000
  T1                          89 (12.9%)    550 (19.1%)        
  T2                          84 (12.2%)    451 (16%)          
  T3                          240 (34.8%)   1,030 (36.2%)      
  T4                          276 (40.1%)   816 (28.7%)        
  **Lymph-node metastasis**                                    0.000
  N0                          182 (26.5%)   1,057 (37.3%)      
  N1                          176 (25.6%)   551 (19.5%)        
  N2                          104 (15.1%)   491 (17.4%)        
  N3                          225 (32.8%)   727 (27.1%)        
  **CEA**                                                      0.000
  Positive                    185 (30%)     450 (17.6%)        
  Negative                    432 (70%)     2,106 (82.4%)      
  **AFP**                                                      0.003
  Positive                    18 (3%)       151 (6.1%)         
  Negative                    583 (97%)     2,312 (93.9%)      
  **CA19-9**                                                   0.000
  Positive                    178 (29.3%)   446 (17.9%)        
  Negative                    429 (70.7%)   2,048 (82.1%)      
  **CA125**                                                    0.775
  Positive                    31 (5.2%)     116 (4.8%)         
  Negative                    557 (94.7%)   2,212 (95.2%)      
  **S100**                                                     0.000
  Positive                    432 (87.4%)   1,585 (76.7%)      
  Negative                    62 (12.6%)    481 (23.3%)        
  **EGFR**                                                     0.992
  Positive                    324 (61.5%)   1,342 (61.5%)      
  Negative                    203 (38.5%)   840 (38.5%)        
  **HER2**                                                     0.000
  \>++                        219 (41.4%)   1,109 (50.8%)      
  ≤++                         310 (58.6%)   1,075 (49.2%)      

###### 

Univariate and multivariate analyses of prognostic factors with/without mucinous component after radical D2 gastrectomy

  Variables          *β*      HR (95% CI)            *P*-value
  ------------------ -------- ---------------------- -----------
  **Univariate**                                     
  T stage            0.79     2.203 (1.948--2.492)   0.000
  N stage            0.673    1.96 (1.792--2.143)    0.000
  Age                0.098    1.103 (1.021--1.192)   0.013
  Location           −0.125   0.882 (0.799--0.974)   0.013
  Borrmann type      −0.13    0.878 (0.832--0.926)   0.019
  CEA                0.735    2.086 (1.702--2.557)   0.000
  AFP                0.734    2.084 (1.447--3.002)   0.000
  CA19-9             0.675    1.963 (1.607--2.398)   0.000
  CA125              1.262    3.531 (2.557--4.875)   0.000
  S100               1.165    3.206 (2.16--4.785)    0.000
  **Multivariate**                                   
  T stage            0.438    1.549 (1.258--1.908)   0.000
  N stage            0.52     1.682 (1.483--1.907)   0.000
  CEA                0.345    1.412 (1.097--1.817)   0.007

###### 

Higher proportions of mucinous component correlated with more advanced tumor stage and positive CEA, CA19-9, EGFR, and HER2[\*](#tfn1-ott-11-967){ref-type="table-fn"}

  Variables                   MGC, n=176    GAM, n=514    *P*-value
  --------------------------- ------------- ------------- -----------
  **Age, years**                                          0.624
  ≤30                         2 (1.1%)      10 (1.9%)     
  31--40                      7 (2.7%)      40 (7.8%)     
  41--50                      33 (18.8%)    103 (20%)     
  51--60                      66 (37.5%)    185 (36%)     
  61--70                      47 (26.7%)    126 (24.5%)   
  71--80                      20 (11.4%)    47 (9.1%)     
  \>80                        1 (0.6%)      3 (0.6%)      
  **Sex**                                                 0.139
  Male                        138 (78.4%)   374 (72.8%)   
  Female                      38 (21.6%)    140 (27.2%)   
  **Smoking history**                                     0.897
  Yes                         151 (85.8%)   443 (86.2%)   
  No                          25 (14.2%)    71 (13.8%)    
  **Drinking history**                                    0.251
  Yes                         150 (85.2%)   59 (11.5%)    
  No                          26 (14.8%)    455 (88.5%)   
  **Location**                                            0.272
  Upper                       61 (34.7%)    150 (29.2%)   
  Middle                      25 (14.2%)    93 (18.1%)    
  Lower                       84 (47.7%)    261 (50.8%)   
  Whole                       6 (3.4%)      10 (1.9%)     
  **Macroscopic type**                                    0.008
  Early gastric cancer        13 (8.2%)     74 (14.9%)    
  Borrmann I                  6 (3.8%)      41 (8.2%)     
  Borrmann II                 32 (20.1%)    121 (24.3%)   
  Borrmann III                83 (52.2%)    207 (41.6%)   
  Borrmann IV                 25 (15.7%)    54 (12.8%)    
  **Depth on invasion**                                   0.000
  T1                          15 (8.5%)     74 (14.4%)    
  T2                          20 (11.4%)    64 (12.5%)    
  T3                          55 (31.8%)    185 (36%)     
  T4                          85 (48.3%)    191 (37.2%)   
  **Lymph-node metastasis**                               0.000
  N0                          37 (20.3%)    145 (28.3%)   
  N1                          82 (46.6%)    145 (18.3%)   
  N2                          17 (16.3%)    87 (17%)      
  N3                          38 (16.9%)    187 (36.5%)   
  **CEA**                                                 0.04
  Positive                    58 (36.3%)    127 (27.8%)   
  Negative                    102 (63.8%)   330 (72.2%)   
  **AFP**                                                 0.137
  Positive                    2 (1.3%)      16 (3.6%)     
  Negative                    156 (98.7%)   427 (96.4%)   
  **CA19-9**                                              0.001
  Positive                    63 (39.1%)    115 (25.8%)   
  Negative                    98 (60.9%)    331 (74.2%)   
  **CA125**                                               0.416
  Positive                    10 (6.5%)     21 (4.8%)     
  Negative                    143 (93.5%)   414 (95.2%)   
  **S100**                                                0.067
  Positive                    94 (82.5%)    338 (88.9%)   
  Negative                    20 (17.5%)    42 (11.1%)    
  **EGFR**                                                0.006
  Positive                    61 (50.8%)    263 (64.6%)   
  Negative                    59 (49.2%)    144 (35.4%)   
  **HER2**                                                0.02
  \>++                        39 (32.3%)    180 (44.1%)   
  ≤++                         82 (67.7%)    228 (55.9%)   

**Note:**

\>++ and FISH test-positive.

**Abbreviations:** MGC, mucinous gastric carcinoma; GAM, gastric adenocarcinoma with mucinous component; FISH, fluorescence in situ hybridization.

###### 

Univariate and multivariate analyses of prognostic factors with mucinous component after radical D2 gastrectomy

  Variables          *β*     HR (95% CI)            *P*-value
  ------------------ ------- ---------------------- -----------
  **Univariate**                                    
  T stage            0.758   2.134 (1.642--2.773)   0
  N stage            0.734   2.084 (1.722--2.523)   0
  Borrmann type      0.158   1.172 (1.027--1.337)   0.019
  CEA                0.743   2.102 (1.454--3.039)   0
  AFP                1.303   3.679 (1.494--9.056)   0.005
  CA19-9             0.773   2.167 (1.504--3.123)   0
  CA125              1.041   2.831 (1.476--5.429)   0.002
  S100               0.934   2.543 (1.102--5.873)   0.029
  **Multivariate**                                  
  N stage            0.518   1.679 (1.281--2.2)     0
  CEA                0.59    1.804 (1.076--3.025)   0.025
